Novel Radiopharmaceuticals

The Novel Radiopharmaceuticals research group, led by Prof. Marek Pruszyński, is dedicated to advancing targeted, personalized medicine through the design and synthesis of innovative diagnostic and therapeutic molecular radiopharmaceuticals.

Our main research areas include:

production of novel radioisotopes
preparation, radiochemical separation, and recovery of target materials for radioisotope production
development of new radiopharmaceuticals for diagnostic and therapeutic applications
radiolabelled nanomaterials for biomedical applications
preclinical in vitro and in vivo evaluation

The Novel Radiopharmaceuticals research group

To learn more about the group, click and visit the following pages:

This project has received funding from the European Union Horizon 2020 research and innovation
programme under grant agreement No 857470 and from European Regional Development Fund
via Foundation for Polish Science International Research Agenda PLUS programme grant
No MAB PLUS/2018/8.

The project is co-financed from the state budget within the framework of the undertaking of the Minister of Science and Higher Education "Support for the activities of Centers of Excellence established under Horizon 2020".

Grant: 5 143 237,70 EUR
Total value: 29 971 365,00 EUR
Date of signing the funding agreement: December 2023

The purpose of the undertaking is to support entities of the higher education and science system that have received funding from the European Union budget in the competition H2020-WIDESPREAD-2018-2020/WIDESPREAD-01-2018-2019: Teaming Phase 2. in the preparation, implementation and updating of activities, maintenance of material resources necessary for carrying out activities, acquisition and modernization of scientific and research apparatus, maintenance and development of personnel potential necessary for the implementation of activities, and dissemination of the results of scientific activities.

Search form

Novel Radiopharmaceuticals

Our main research areas include:

To learn more about the group, click and visit the following pages: